Hidetoshi Nitta1, Hideo Baba2, Kazuya Sugimori3, Junji Furuse4, Shinichi Ohkawa5, Kazuhide Yamamoto6, Hironobu Minami7, Mototsugu Shimokawa8, G O Wakabayashi9, Keisuke Aiba10. 1. Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan. 2. Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan hdobaba@kumamoto-u.ac.jp. 3. Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan. 4. Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan. 5. Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan. 6. Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Okayama, Japan. 7. Department of Medicine, Division of Medical Oncology/Hematology, Kobe University, Hospital and Graduate School of Medicine, Kobe City, Hyogo, Japan. 8. Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan. 9. Department of Surgery, Iwate Medical University School of Medicine, Morioka, Japan. 10. Department of Internal Medicine, Division of Clinical Oncology/Hematology, Jikei University School of Medicine, Tokyo, Japan.
Abstract
BACKGROUND: This study investigated the prevalence of chemotherapy-induced nausea and vomiting (CINV) in patients with hepatobiliary-pancreatic (HBP) cancer in a prospective nationwide survey. PATIENTS AND METHODS: One hundred patients with HBP cancer (biliary tract cancer; n=70, hepatocellular carcinoma; n=20, and pancreatic cancer; n=10) who received chemotherapy for the first time were analyzed. Medical personnel were surveyed to examine the accuracy of their predicted frequency of CINV. RESULTS: The compliance rate with the Japanese guideline with highly emetogenic chemotherapy was 36/89 (40%). Although the prevalence of CINV in patients with HBP cancer was significantly lower than that of the total 1,910 patients with cancer, the prevalence of delayed CINV in patients with HBP cancer was as high as 28%. The survey results suggested that the medical staff tended to overestimate the incidence of CINV. CONCLUSION: CINV appears to be controlled under management according to the guidelines, but delayed nausea remains prevalent and requires further investigation. Copyright
BACKGROUND: This study investigated the prevalence of chemotherapy-induced nausea and vomiting (CINV) in patients with hepatobiliary-pancreatic (HBP) cancer in a prospective nationwide survey. PATIENTS AND METHODS: One hundred patients with HBP cancer (biliary tract cancer; n=70, hepatocellular carcinoma; n=20, and pancreatic cancer; n=10) who received chemotherapy for the first time were analyzed. Medical personnel were surveyed to examine the accuracy of their predicted frequency of CINV. RESULTS: The compliance rate with the Japanese guideline with highly emetogenic chemotherapy was 36/89 (40%). Although the prevalence of CINV in patients with HBP cancer was significantly lower than that of the total 1,910 patients with cancer, the prevalence of delayed CINV in patients with HBP cancer was as high as 28%. The survey results suggested that the medical staff tended to overestimate the incidence of CINV. CONCLUSION:CINV appears to be controlled under management according to the guidelines, but delayed nausea remains prevalent and requires further investigation. Copyright
Authors: Andrew E Hendifar; Maria Q B Petzel; Teresa A Zimmers; Crystal S Denlinger; Lynn M Matrisian; Vincent J Picozzi; Lola Rahib Journal: Oncologist Date: 2018-12-27 Impact factor: 5.837